Saturday 17 October 2026
Export CTOR’s income statement to Excel — free account
Citius Oncology, Inc.
CTOR Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS was flat, free cash flow was flat and total debt rose 79.3%, each against the same quarter a year earlier.
0.75
0.00
0.00%
Follow CTOR
| Sep '21 | Dec '21 | Sep '22 | Dec '22 | Sep '23 | Dec '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.93 | 1.33 | 11.86 | 0.37 | 0.03 | 0.34 | 0.56 |
Net Debt/EBITDA |
0.00 | (12.94) | (1.40) | 2.09 | (1.61) | (0.31) | (0.21) | (0.40) |
Debt/Assets |
0.00% | 103.40% | 75.18% | 0.00% | 40.85% | 0.47% | 5.20% | 13.19% |
Debt/Equity |
— | (12.94) | (966.00) | 0.00 | 0.76 | (0.17) | 0.10 | 0.30 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | (0.13) | 0.00 | (0.25) | (0.01) | 0.22 |
Capex/Depreciation |
0.00 | — | 0.00 | — | — | — | 0.00 | 0.00 |
Interest Coverage |
— | — | — | (0.28) | — | — | — | (107.90) |
| 0.00% | 0.00% | (7,394.17%) | 220.56% | (98.12%) | 20.55% | (95.80%) | (54.42%) | |
| 0.00% | (15.98%) | 198.64% | 1.11% | (21.91%) | 4.02% | (26.94%) | (26.72%) | |
ROIC |
0.00% | (5.23%) | (44.72%) | (153.31%) | (16.82%) | 0.00% | (25.45%) | (27.10%) |
Return on Tangible Assets |
0.00% | 100.00% | 596.87% | 110.22% | 95.38% | (121.72%) | 97.32% | 112.81% |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | — | 0.00% | — | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | 0.00% | — | 0.00% | 0.00% |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | (0.03) | 0.00 | (0.26) | (0.07) | (0.15) |
Cash per Share |
— | 0.00 | — | 0.16 | 0.00 | 0.01 | 0.00 | 0.05 |
Shareholders Equity per Share |
— | 0.00 | 0.00 | 0.19 | 0.38 | (0.85) | 0.68 | 0.61 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 0.00 | 0.19 | 0.38 | (0.85) | 0.68 | 0.61 |
Free Cash Flow |
0.00 | — | 0.00 | (0.05) | — | (0.60) | (4.87) | (11.24) |
Working Capital |
— | (0.01) | 0.06 | 0.35 | (13.31) | (1.99) | (21.73) | (21.95) |
Capital Expenditures |
0.00 | — | 0.00 | — | — | — | (5.00) | (5.75) |
Net Current Asset Value |
— | (0.01) | 0.06 | (67.47) | (14.46) | (74.55) | (27.26) | (28.53) |
| Other line items | ||||||||
Quick Ratio |
— | 0.00 | 0.00 | 9.09 | 0.00 | 0.02 | 0.00 | 0.08 |
Depreciation/Fixed assets |
0.00 | — | 0.00 | — | — | — | — | — |
Cash ROIC |
0.00% | 0.00% | 0.00% | (7.56%) | 0.00% | 37.35% | (9.65%) | (18.10%) |
Accounts Payable Turnover |
— | — | — | — | — | — | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | — | 0.00 |
Average Days of Payables |
— | — | — | — | 0.00 | — | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.00 | 0.00 | — | (0.03) | 0.00 | (0.26) | 0.00 | (0.07) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.07) | (0.08) |
Average Payables |
— | — | — | — | — | — | 2.50 | 8.47 |
Average Inventory |
— | — | — | — | — | — | — | 15.28 |
Average Assets |
— | 0.06 | 0.19 | 34.22 | 57.96 | 60.18 | 78.50 | 92.66 |
Average Common Equity |
— | — | (0.01) | 0.17 | 12.94 | 11.77 | 22.08 | 45.50 |
Capex to Sales |
0.00 | — | 0.00 | — | — | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Oct 2026